Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells
• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Friedman, Jay [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:90 ; year:2019 ; pages:38-44 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2019.01.017 |
|---|
| Katalog-ID: |
ELV045976597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045976597 | ||
| 003 | DE-627 | ||
| 005 | 20230624121121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2019.01.017 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000695.pica |
| 035 | |a (DE-627)ELV045976597 | ||
| 035 | |a (ELSEVIER)S1368-8375(19)30028-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Friedman, Jay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| 264 | 1 | |c 2019 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. | ||
| 650 | 7 | |a haNK |2 Elsevier | |
| 650 | 7 | |a Radiation |2 Elsevier | |
| 650 | 7 | |a Avelumab |2 Elsevier | |
| 650 | 7 | |a Head and neck cancer |2 Elsevier | |
| 650 | 7 | |a Cetuximab |2 Elsevier | |
| 650 | 7 | |a ADCC |2 Elsevier | |
| 700 | 1 | |a Padget, Michelle |4 oth | |
| 700 | 1 | |a Lee, John |4 oth | |
| 700 | 1 | |a Schlom, Jeffrey |4 oth | |
| 700 | 1 | |a Hodge, James |4 oth | |
| 700 | 1 | |a Allen, Clint |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:90 |g year:2019 |g pages:38-44 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2019.01.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 90 |j 2019 |h 38-44 |g 7 | ||
| author_variant |
j f jf |
|---|---|
| matchkey_str |
friedmanjaypadgetmichelleleejohnschlomje:2019----:ietnatbddpneteleitdyooiiyfednncsumuclcrioaelb |
| hierarchy_sort_str |
2019 |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2019 |
| allfields |
10.1016/j.oraloncology.2019.01.017 doi GBV00000000000695.pica (DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 DE-627 ger DE-627 rakwb eng 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Friedman, Jay verfasserin aut Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier Padget, Michelle oth Lee, John oth Schlom, Jeffrey oth Hodge, James oth Allen, Clint oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:90 year:2019 pages:38-44 extent:7 https://doi.org/10.1016/j.oraloncology.2019.01.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 90 2019 38-44 7 |
| spelling |
10.1016/j.oraloncology.2019.01.017 doi GBV00000000000695.pica (DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 DE-627 ger DE-627 rakwb eng 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Friedman, Jay verfasserin aut Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier Padget, Michelle oth Lee, John oth Schlom, Jeffrey oth Hodge, James oth Allen, Clint oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:90 year:2019 pages:38-44 extent:7 https://doi.org/10.1016/j.oraloncology.2019.01.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 90 2019 38-44 7 |
| allfields_unstemmed |
10.1016/j.oraloncology.2019.01.017 doi GBV00000000000695.pica (DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 DE-627 ger DE-627 rakwb eng 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Friedman, Jay verfasserin aut Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier Padget, Michelle oth Lee, John oth Schlom, Jeffrey oth Hodge, James oth Allen, Clint oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:90 year:2019 pages:38-44 extent:7 https://doi.org/10.1016/j.oraloncology.2019.01.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 90 2019 38-44 7 |
| allfieldsGer |
10.1016/j.oraloncology.2019.01.017 doi GBV00000000000695.pica (DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 DE-627 ger DE-627 rakwb eng 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Friedman, Jay verfasserin aut Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier Padget, Michelle oth Lee, John oth Schlom, Jeffrey oth Hodge, James oth Allen, Clint oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:90 year:2019 pages:38-44 extent:7 https://doi.org/10.1016/j.oraloncology.2019.01.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 90 2019 38-44 7 |
| allfieldsSound |
10.1016/j.oraloncology.2019.01.017 doi GBV00000000000695.pica (DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 DE-627 ger DE-627 rakwb eng 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Friedman, Jay verfasserin aut Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells 2019 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier Padget, Michelle oth Lee, John oth Schlom, Jeffrey oth Hodge, James oth Allen, Clint oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:90 year:2019 pages:38-44 extent:7 https://doi.org/10.1016/j.oraloncology.2019.01.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 90 2019 38-44 7 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:90 year:2019 pages:38-44 extent:7 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:90 year:2019 pages:38-44 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
haNK Radiation Avelumab Head and neck cancer Cetuximab ADCC |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Friedman, Jay @@aut@@ Padget, Michelle @@oth@@ Lee, John @@oth@@ Schlom, Jeffrey @@oth@@ Hodge, James @@oth@@ Allen, Clint @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV045976597 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045976597</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624121121.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2019.01.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000695.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045976597</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(19)30028-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Friedman, Jay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">haNK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Avelumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cetuximab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ADCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padget, Michelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlom, Jeffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodge, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allen, Clint</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:38-44</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2019.01.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2019</subfield><subfield code="h">38-44</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Friedman, Jay |
| spellingShingle |
Friedman, Jay ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| authorStr |
Friedman, Jay |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier haNK Elsevier Radiation Elsevier Avelumab Elsevier Head and neck cancer Elsevier Cetuximab Elsevier ADCC |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m p mp j l jl j s js j h jh c a ca |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| ctrlnum |
(DE-627)ELV045976597 (ELSEVIER)S1368-8375(19)30028-4 |
| title_full |
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| author_sort |
Friedman, Jay |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
38 |
| author_browse |
Friedman, Jay |
| container_volume |
90 |
| physical |
7 |
| class |
610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Friedman, Jay |
| doi_str_mv |
10.1016/j.oraloncology.2019.01.017 |
| dewey-full |
610 650 |
| title_sort |
direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| title_auth |
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| abstract |
• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. |
| abstractGer |
• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. |
| abstract_unstemmed |
• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| url |
https://doi.org/10.1016/j.oraloncology.2019.01.017 |
| remote_bool |
true |
| author2 |
Padget, Michelle Lee, John Schlom, Jeffrey Hodge, James Allen, Clint |
| author2Str |
Padget, Michelle Lee, John Schlom, Jeffrey Hodge, James Allen, Clint |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2019.01.017 |
| up_date |
2024-07-06T19:00:07.469Z |
| _version_ |
1803857331454214144 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045976597</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624121121.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2019.01.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000695.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045976597</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(19)30028-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Friedman, Jay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• haNKs are an off-the-shelf cellular therapy that kill head and neck cancer cells. • Cetuximab and Avelumab enhance tumor cell killing by haNKs through ADCC. • Ionizing radiation may enhance ADCC through increased expression of antibody targets. • haNKs plus cetuximab or avelumab warrant evaluation in clinical trials for HNSCC.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">haNK</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Radiation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Avelumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cetuximab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ADCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padget, Michelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlom, Jeffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hodge, James</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allen, Clint</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:38-44</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2019.01.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2019</subfield><subfield code="h">38-44</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.400222 |